Nymox Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

3 years ago

by David Miller

975 Views

Written by David Miller

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!